Meeting
2021 ASCO Annual Meeting
The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospective study.
Authors
Karen Kelly
University of California Davis Comprehensive Cancer Center, Sacramento, CA
Karen Kelly , Shuai Chen , Joanna B Eldredge , David Joseph Benjamin , Matthew C Mulroy , Nadeem Tabbara , John Sharp , Jonathan Wade Goldman , Matthew A. Gubens , Jeremy P. Harris , Megan Eileen Daly , Sandip Pravin Patel , Jason Chan , Amy Lauren Cummings , Viola Weijia Zhu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9059)
DOI
10.1200/JCO.2021.39.15_suppl.9059
Abstract #
9059
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.
First Author: Laurent Mhanna
Poster
2019 ASCO Annual Meeting
The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan.
First Author: Kiyotaka Yoh
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates
Poster
2023 ASCO Breakthrough
Differential therapeutic benefit of platinum-doublet chemotherapies with ICIs based on smoking status plus PD-L1 expression in advanced NSCLC patients.
First Author: Akito Fukuda